Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0JXYIZ
ADC Name
DS-9606
Synonyms
DS-9606a; DS9606; DS 9606
   Click to Show/Hide
Organization
Daiichi Sankyo Co., Ltd.
Drug Status
Phase 1
Indication
In total 2 Indication(s)
Ovarian cancer [ICD11:2C73]
Phase 1
Testicular cancer [ICD11:2C80]
Phase 1
Antibody Name
Undisclosed
Antigen Name
Claudin-6 (CLDN6)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
Puchem SID
355210663
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05394675
Phase 1
A phase 1, first-in-human study of DS-9606a in patients with tumor types known to express claudin-6 (CLDN6).
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05394675  Clinical Status Phase 1
Clinical Description A phase 1, first-in-human study of DS-9606a in patients with tumor types known to express claudin-6 (CLDN6).
References
Ref 1 A Phase 1, First-in-Human Study of DS-9606a in Patients With Tumor Types Known to Express Claudin-6 (CLDN6), NCT05394675

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.